IP Library Granted Patent US 12,421,524
Granted Patent B2
US 12,421,524 · App. 17/277,663 · Granted Sep 23, 2025

Expression vectors for eukaryotic expression systems

Inventors: Zhimei Du (Basking Ridge, NJ); Bo Jiang (Westfield, NJ); Xiaoyan Tang (Wayne, NJ)
Assignee: Merck Sharp & Dohme LLC
C12N15/85C07K16/06C07K2317/14C12N2510/02C12N2800/90C12N2820/55C12N2830/40C12N2840/203
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,421,524
App. No.
17/277,663
Granted
Sep 23, 2025
Kind
B2
Abstract

The invention provides expression vectors for expressing recombinant proteins (e.g., biologics) in mammalian cells. Also provided are host cells comprising the expression vectors, methods of producing the recombinant proteins, and methods of propagating the expression vectors.

Claims (38)

1. An expression vector comprising:

(a) a first expression cassette comprising the following elements in the order of upstream to downstream: a promoter operably linked to an insertion site for a gene of interest (GOI), an internal ribosome entry site (IRES), wherein the IRES consists of a polynucleotide sequence of SEQ ID NO: 3, a polynucleotide encoding a eukaryotic selectable marker, and a polyadenylation (polyA) signal;

(b) a second expression cassette comprising a polynucleotide encoding a bacterial selectable marker; and

(c) a bacterial plasmid origin of replication;

wherein optionally the first expression cassette further comprises one or more regulatory element; and

wherein optionally the regulatory element is an enhancer, an insulator, a locus control region (LCR), a matrix attachment region (MAR), a scaffold attachment region (SAR), an expression augmenting sequence element (EASE), an adenovirus tripartite leader (TPL), or a ubiquitous chromatin opening element (UCOE).

2. The expression vector of claim 1 , further comprising two inverted terminal repeat (ITR) sequences flanking the first expression cassette.

3. The expression vector of claim 2 , wherein

(a) the eukaryotic selectable marker is a neomycin phosphotransferase, a histidinol dehydrogenase, a hygromycin B phosphotransferase, a xanthine-guanine phosphoribosyltransferase, a dihydrofolate reductase, a tryptophan synthetase, a puromycin N-acetyl-transferase, a thymidine kinase, an adenine phosphoribosyl transferase, a glutamine synthetase, an adenosine deaminase, or metallothionein-1; wherein optionally the eukaryotic selectable marker is a glutamine synthetase or a neomycin phosphotransferase;

(b) the promoter is a human cytomegalovirus (CMV) immediate-early promoter, a human elongation factor 1 alpha (EF1a) promoter, a SV40 promoter, a phosphoglycerate kinase 1 (PGK1) promoter, a human ubiquitin C (Ubc) promoter, a human β-actin promoter, a CAG promoter, a yeast transcription elongation factor 1 (TEF1) promoter, a yeast glyceraldehyde 3-phosphate dehydrogenase (GAPDH) promoter, or a yeast alcohol dehydrogenase 1 (ADH1) promoter; wherein optionally the promoter is a human CMV immediate-early promoter;

(c) the enhancer is a CMV immediate-early enhancer; and/or

(d) the insulator is HS4.

4. An expression vector comprising:

(a) a first expression cassette comprising the following elements in the order of upstream to downstream: a first insulator, an EASE, a promoter, a TPL, an insertion site for a GOI, an IRES, a polynucleotide encoding a eukaryotic selectable marker, a polyA signal, and a second insulator;

(b) two ITR sequences flanking the first expression cassette;

(c) a second expression cassette comprising a polynucleotide encoding a bacterial selectable marker; and

(d) a bacterial plasmid origin of replication;

wherein optionally the first expression cassette further comprises an enhancer;

wherein optionally the enhancer is located between the EASE and the promoter;

wherein optionally the enhancer is a human CMV immediate-early enhancer;

wherein optionally the promoter is a human CMV immediate-early promoter;

wherein optionally the first and the second insulators are HS4;

wherein optionally the eukaryotic selectable marker is a glutamine synthetase or a neomycin phosphotransferase; and

wherein the IRES consists of a polynucleotide sequence of SEQ ID NO: 3.

5. An expression vector,

(a) comprising a polynucleotide sequence of SEQ ID NO: 6 or 8;

(b) consisting of a polynucleotide sequence of SEQ ID NO: 6 or 8; or

(c) consisting essentially of a polynucleotide sequence of SEQ ID NO: 6 or 8.

6. The expression vector of claim 5 , wherein the polynucleotide sequence is SEQ ID NO:8.

7. The expression vector of claim 4 , wherein the first expression cassette further comprises the GOI encoding

(a) a therapeutic or prophylactic protein;

(b) a light chain of a monoclonal antibody; or

(c) a heavy chain of a monoclonal antibody.

8. An isolated host cell comprising the expression vector of claim 7 , wherein optionally the host cell is a mammalian host cell or a bacterial host cell; wherein optionally the mammalian host cell is a CHO cell; and wherein optionally the endogenous glutamine synthetase gene of the CHO cell is knocked out.

9. A method of producing a polypeptide encoded by a GOI, comprising culturing the host cell of claim 8 in vitro under conditions in which the polypeptide is expressed, wherein the expression vector comprises the GOI encoding the polypeptide; and wherein the method further comprises recovering the polypeptide from the culture.

10. A method of propagating an expression vector, comprising culturing the host cell of claim 8 in vitro under conditions in which the expression vector is replicated; and wherein optionally the method further comprises recovering the expression vector from the culture.

11. An isolated host cell comprising a first expression vector of claim 4 and a second expression vector of claim 4 , wherein the first expression vector further comprises a first GOI encoding a light chain of a monoclonal antibody or fragments thereof; wherein the second expression vector further comprises a second GOI encoding a heavy chain of the monoclonal antibody or fragments thereof; and wherein the eukaryotic selectable marker of the first expression vector is different from the eukaryotic selectable marker of the second expression vector.

12. A method of producing a monoclonal antibody, comprising culturing the host cell of claim 11 in vitro under conditions in which the light chain of the monoclonal antibody and the heavy chain of the monoclonal antibody are expressed; and wherein optionally the method further comprises recovering the monoclonal antibody from the culture.

Assignments (2)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2021
From: DU, ZHIMEI; JIANG, BO; TANG, XIAOYAN
To: MERCK SHARP & DOHME CORP.
Reel/Frame 055642/0543 →
Continuity (2)
Provisional Application 62735417 · Sep 24, 2018
Related Publication 20220033845A1 · Feb 3, 2022
References Cited (78)
US 4816567A · Cabilly et al. · 1989 [cited by applicant]
US 8663989B2 · Stitz · 2014 [cited by applicant]
US 9752159B2 · Krishnan et al. · 2017 [cited by applicant]
US 20030082735A1 · McGrew · 2003 [cited by examiner]
US 20060141577A1 · Otte et al. · 2006 [cited by applicant]
US 20060212949A1 · Alphey · 2006 [cited by examiner]
US 20090042297A1 · George, Jr. et al. · 2009 [cited by applicant]
US 20110014624A1 · McCarthy et al. · 2011 [cited by applicant]
US 20120301919A1 · Yang et al. · 2012 [cited by applicant]
US 20140134719A1 · Deshpande · 2014 [cited by examiner]
US 20140227786A1 · Stitz · 2014 [cited by applicant]
US 20180163230A1 · Bublot et al. · 2018 [cited by applicant]
US 20190055580A1 · McGrew · 2019 [cited by examiner]
CN 100494370C · 2009 [cited by applicant]
CN 108330135A · 2018 [cited by applicant]
EP 2733202A1 · 2014 [cited by applicant]
EP 3101134A1 · 2016 [cited by applicant]
KR 20030086429A · 2003 [cited by applicant]
WO 1997025420A1 · 1997 [cited by applicant]
WO 2013092743A2 · 2013 [cited by applicant]
WO 2015016786A1 · 2015 [cited by applicant]
WO 2015021077A1 · 2015 [cited by applicant]
WO 2016003368A1 · 2016 [cited by applicant]
WO 2016074016A1 · 2016 [cited by applicant]
WO WO2017081082A2 · 2017 [cited by examiner]
WO 2017106795A1 · 2017 [cited by applicant]
WO 2018006880A1 · 2018 [cited by applicant]
WO 2018161017A1 · 2018 [cited by applicant]
PiggyBac Product Insert, SBI, System Biosciences (Year: 2014). [cited by examiner]
PGEM vector map, Author: Promega, 1999. (Year: 1999). [cited by examiner]
X65308.2, pGEM vector sequence deposited in Genbank, Author: Promega, 1999. (Year: 1999). [cited by examiner]
Moritz (Sci Rep 5, 16952, 2015) (Year: 2015). [cited by examiner]
Lonza (Retrieved from the internet Sep. 19, 2024 <https://dam.lonza.com/dmm3bwsv3/assetstream.aspx?assetid=12674&mediaformatid=10061&destinationid=10016>). (Year: 1992). [cited by examiner]
Aldrich, Teri L. et al., Improved bicistronic mammalian expression vectors using expression augmenting sequence element (EASE), Cytotechnology, 1998, 9-17, 28. [cited by applicant]
Berger, Shelley L. et al., An operational definition of epigenetics, Genes & Development, 2009, 781-783, 23. [cited by applicant]
Birch, John R. et al., Antibody production, Advanced Drug Delivery Reviews, 2006, 671-685, 58. [cited by applicant]
Bire, Solenne et al., Optimization of the piggyBac Transposon Using mRNA and Insulators: Toward a More Reliable Gene Delivery System, PLoS One, 2013, 1-10, 8(12): e82559. [cited by applicant]
Bochkov, Yury A. et al., Translational efficiency of EMCV IRES in bicistronic vectors is dependent upon IRES sequence and gene location, BioTechniques, 2006, 283-292, 41. [cited by applicant]
Carswell, Susan et al., Efficiency of Utilization of the Simian Virus 40 Late Polyadenylation Site: Effects of Upstream Sequences, Molecular and Cellular Biology, 1989, 4248-4258, 9(10). [cited by applicant]
Cary, Lynne Csiszar, et al., Transposon Mutagenesis of Baculoviruses: Analysis of Trichoplusia ni Transposon IFP2 Insertions within the FP-Locus of Nuclear Polyhedrosis Viruses, Virology, 1989, 156-169, 172. [cited by applicant]
Chung, Jay H. et al., A 5′ Element of the Chicken Beta-Globin Domain Serves as an Insulator in Human Erythroid Cells and Protects against Position Effect in [cited by applicant]
Chung, Jay H. et al., Characterization of the chicken beta-globin insulator, PNAS USA, 1997, 575-580, 94. [cited by applicant]
Clackson et al., Making Antibody Fragments Using Phage Display Libraries, Nature, 1991, pp. 624-628, vol. 352. [cited by applicant]
Clontech Laboratories Inc. pIRESneo3 Vector Information. May 20, 2008. Protocol No. PT2645-5. Version No. PR852532. Accessed Dec. 31, 2019. https://www.takarabio.com/assets/documents/Vector Documents/PT3645-5.pdf. first… [cited by applicant]
Dillon, Niall et al., Transcriptional regulation of multigene loci: multilevel control, Trends Genet., 1993, 134-137, 9. [cited by applicant]
Duke, Gregory M. et al., Sequence and Structural Elements That Contribute to Efficient Encephalomyocarditis Virus RNA Translation, Journal of Virology, 1992, 1602-1609, 66(3). [cited by applicant]
Fiers, W. et al., Complete nucleotide sequence of SV40 DNA, Nature, 1978, 113-120, 273. [cited by applicant]
Gasser, S.M. et al., A glimpse at chromosomal order, Trends Genet., 1987, 16-22, 3. [cited by applicant]
GenBank EF467048.1, (3 pages). [cited by applicant]
GenBank LC417349.1, (2 pages. [cited by applicant]
GenBank X17403.1 (89 pages). [cited by applicant]
GenBank: AF193761.1 (4 pages). [cited by applicant]
GenBank: AH001475 (2 pages). [cited by applicant]
GenBank: J02400.1 (17 pages). [cited by applicant]
GenBank: J04364.2 (2 pages). [cited by applicant]
GenBank: M81861.1, (3 pages). [cited by applicant]
GenBank: U78775.2 (2 pages). [cited by applicant]
Grosveld, Frank et al., Position-Independent, High-Level Expression of the Human Beta-Globin Gene in Transgenic Mice, Cell, 1987, 975-985, 51. [cited by applicant]
Hartzell, Stephen W. et al., Mapping of the late promoter of simian virus 40, PNAS USA, 1984, 23-27, 81. [cited by applicant]
Jang, Sung K. et al., Cap-independent translation of encephalomyocarditis virus RNA: structural elements of the internal ribosomal entry site and involvement of a cellular 57-kD RNA-binding protein, Genes & Development,… [cited by applicant]
Kaufman, Randal J. et al., Improved vectors for stable expression of foreign genes in mammalian cells by use of the untranslated leader sequence from EMC virus, Nucleic Acids Research, 1991, 4485-4490, 19. [cited by applicant]
Kaufman, Randal J., Identification of the components necessary for adenovirus translational control and their utilization in cDNA expression vectors, PNAS USA, 1985, 689-693, 82. [cited by applicant]
Kellum, Rebecca et al., A Position-Effect Assay for Boundaries of Higher Order Chromosomal Domains, Cell, 1991, 941-950, 64. [cited by applicant]
Kohler et al., Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity, Nature, 1975, pp. 495-497, vol. 256. [cited by applicant]
Ludwig, Dale L., Mammalian Expression Cassette Engineering for High-Level Protein Production, BioProcess International, 2006, S14-S23, 4. [cited by applicant]
Marks et al., By passing Immunization, J. Mol. Biol., 1991, pp. 581-597, 222. [cited by applicant]
McBratney, Susan et al., Internal initiation of translation, Current Opinion in Cell Biology, 1993, 961-965, 5. [cited by applicant]
Phi-Van, Loc et al., The Chicken Lysozyme 5′ Matrix Attachment Region Increases Transcription from a Heterologous Promoter in Heterologous Cells and Dampens Position Effects on the Expression of Transfected Genes, Molec… [cited by applicant]
Presta, Leonard G. et al., Selection, design, and engineering of therapeutic antibodies, J. Allergy Clin. Immunol., 2005, 731-736, 116(4). [cited by applicant]
Schuler, A., Development of a novel expression system for the production of recombinant proteins in Chinese hamster ovary cells based on the selection with a metabolic enzyme, Technischen Universitat Carolo-Wilhelmina, … [cited by applicant]
Thein, S.L. et al., Molecular basis for dominantly inherited inclusion body beta-thalassemia, PNAS USA, 1990, 3924-3928, 87. [cited by applicant]
Wurm, Flurian M. et al., Production of recombinant protein therapeutics in cultivated mammalian cells, Nature Biotechnology, 2004, 1393-1398, 22. [cited by applicant]
Fakhro, Samah, Analysis of S/MAR vectors for gene therapy in muscle, University of London, 2011, 1-336, N/A. [cited by applicant]
Li, Qin et al., Effect of β-globin MAR characteristic elements on transgene expression, Molecular Medicine Reports, 2013, 1871-1874, 7. [cited by applicant]
Sharma, Nynne et al., The Impact of cHS4 Insulators on DNA Transposon Vector Mobilization and Silencing in Retinal Pigment Epithelium Cells, PLoS One, 2012, 1-12, 10:e48421. [cited by applicant]
Author names: Nynne Sharma, Anne Kruse Hollensen, Rasmus O. Bak, Nicklas Heine Staunstrup, Lisbeth Dahl Schrøder, and Jacob Giehm Mikkelsen, Title: The Impact of cHS4 Insulators on DNA Transposon Vector Mobilization and… [cited by applicant]
Author name: Samah Fakhro, Title: Analysis of S/MAR vectors for gene therapy in muscle, pages being submitted: 1-336, publication date: Apr. 2011, publisher details: Diss. Royal Holloway, University of London, PhD Thesi… [cited by applicant]
Author names: Qin LI, Welhua Dong, Tianyun Wang, Zhonghe Liu, Fang Wang, Xiaoyin Wang, Chunpeng Zhao, Junhe Zhang, and Li Wang, Title: Effect of globin MAR characteristic elements on transgene expression, pages being su… [cited by applicant]